IGF1R and cancer: Knowing that numerous patients worldwide have incurable cancers supported by aerobic glycolysis and key oncogenic drivers (such as IGF-1R, Ras/PI3K/Akt, HER2/neu, WNT/β-catenin, TME acidity and EMT) [145,161,162], all pathways efficiently counteracted by citrate sodium in preclinical studies, we strongly believe that the citrate strategy we have proposed since many years [25] should now be considered for clinical trials.